6Y4.F VICORE PHARMA HOLDING AB

Healthcare Biotechnology Frankfurt Exchange
0.9970 EUR
Close of Nov 11, 2026
0.7740 1.86
Market cap
EUR 281M
P/E
-
P/B
3.57x
ROE
-58.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6Y4.F undervalued?

Graham number

The Graham number of VICORE PHARMA HOLDING AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VICORE PHARMA HOLDING AB fundamental analysis

No fundamental analysis for VICORE PHARMA HOLDING AB yet.

VICORE PHARMA HOLDING AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VICORE PHARMA HOLDING AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational…

Full company profile